# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

> **NCT03320707** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 66 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Placebo
- **DRUG:** rHuPH20

## Key facts

- **NCT ID:** NCT03320707
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-16
- **Primary completion:** 2019-08-27
- **Final completion:** 2019-08-27
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03320707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03320707, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03320707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*